Novel MET exon 14 skipping analogs characterized in non-small cell lung cancer patients: A case study.
MET alterations
MET exon 14 skipping analog
NGS
Oncogenic driver
Journal
Cancer genetics
ISSN: 2210-7762
Titre abrégé: Cancer Genet
Pays: United States
ID NLM: 101539150
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
27
10
2020
revised:
25
02
2021
accepted:
08
04
2021
pubmed:
28
4
2021
medline:
21
10
2021
entrez:
27
4
2021
Statut:
ppublish
Résumé
MET exon 14 skipping (METex14) is a validated oncogenic driver in lung cancer and MET tyrosine kinase inhibitors are now available as effective clinical treatments. The majority of known METex14 alterations are typical donor/acceptor splicing or ubiquitination site mutations. Herein, two new METex14 variants were detected in two patients with lung adenocarcinoma by targeted next generation sequencing (NGS). Reverse transcription (RT)-based analysis confirmed that these mutations led to MET exon 14 skipping. Our analysis provided evidence for possible targeted therapy options for patients carrying these MET mutations or similar METex14 analogs.
Identifiants
pubmed: 33905998
pii: S2210-7762(21)00105-8
doi: 10.1016/j.cancergen.2021.04.005
pii:
doi:
Substances chimiques
RNA, Messenger
0
MET protein, human
EC 2.7.10.1
Proto-Oncogene Proteins c-met
EC 2.7.10.1
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
62-67Informations de copyright
Copyright © 2021. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of Competing Interest All authors declare that they have no conflicts of interest.